NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Roundtable on Translating Genomic-Based Research for Health; Board on Health Sciences Policy; Institute of Medicine. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop Summary. Washington (DC): National Academies Press (US); 2014 Mar 6.

Cover of Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests

Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop Summary.

Show details


  • ACOG (American College of Obstetricians and Gynecologists Committee on Genetics). ACOG committee opinion no. 486: Update on carrier screening for cystic fibrosis. Obstetrics & Gynecology. 2011;117(4):1028–1031. [PubMed: 21422883]
  • Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Archives of Pathology & Laboratory Medicine. 2012;136(11):1385–1391. [PubMed: 22332713]
  • Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Pretet JL, Bieche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: A total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project—part 1) Journal of Thoracic Oncology. 2011;6(6):1006–1015. [PubMed: 21532509]
  • Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjo A, Gorgoulis V, Hofler G, Jung A, Kotsinas A, Laurent-Puig P, Lopez-Rios F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E. External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds. Oncologist. 2011;16(4):467–478. [PMC free article: PMC3228116] [PubMed: 21441573]
  • Brawley OW, Goldberg P. How we do harm: A doctor breaks ranks about being sick in America. 1st. New York: St. Martin's Press; 2012.
  • Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. New Biotechnology. 2012;29(6):682–688. [PubMed: 22391147]
  • Chiang A, Million RP. Personalized medicine in oncology: Next generation. Nature Reviews Drug Discovery. 2011;10(12):895–896. [PubMed: 22129983]
  • CMS (Centers for Medicare & Medicaid Services). Forecast summary. Major findings for national health expenditures: 2012–2022. 2013. [September 20, 2013]. http://www​​/Statistics-Trends-and-Reports​/NationalHealthExpendData​/Downloads/Proj2012.pdf.
  • Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nature Reviews Drug Discovery. 2012;11(5):349–350. [PubMed: 22543461]
  • Dequeker E, Ligtenberg MJ, Vander Borght S, van Krieken JH. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: Development and evaluation of quality by a European external quality assessment scheme. Virchows Archiv. 2011;459(2):155–160. [PubMed: 21701884]
  • DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. Journal of Health Economics. 2003;22(2):151–185. [PubMed: 12606142]
  • Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery. 2010;9(4):277–291. [PubMed: 20186141]
  • FDA (U.S. Food and Drug Administration). Guidance for industry and Food and Drug Administration Staff—in vitro companion diagnostic devices. 2011. [October 24, 2013]. http://www​​/deviceregulationandguidance​/guidancedocuments/ucm262292.htm.
  • Gonzalez de Castro D, Angulo B, Gomez B, Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH, Lawrence HJ, Lopez-Rios F. A comparison of three methods for detecting kras mutations in formalin-fixed colorectal cancer specimens. British Journal of Cancer. 2012;107(2):345–351. [PMC free article: PMC3394984] [PubMed: 22713664]
  • Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagnostic Molecular Pathology. 2012;21(1):1–8. [PubMed: 22306669]
  • Longshore JW, Amidon H, Todd HN, Fu J, Christensen M, Tsai J, Hillman G, Halait H, Shieh F, Lawrence J, Lipford E. A methods comparison analysis of the Roche cobas 4800 BRAF V600 mutation test and the Qiagen BRAF RGQ PCR kit on melanoma specimens with challenging attributes. Journal of Molecular Diagnostics. 2012;14(6):716.
  • Moore MW, Babu D, Cotter PD. Challenges in the co-development of companion diagnostics. Personalized Medicine. 2012;9(5):485–496.
  • Quinn B. Payers and the assessment of clinical utility for companion diagnostics. Clinical Pharmacology & Therapeutics. 2010;88(6):751–754. [PubMed: 21081944]
  • van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G, Carneiro F, Celik I, Ciardiello F, Cree IA, Deans ZC, Edsjo A, Groenen PJ, Kamarainen O, Kreipe HH, Ligtenberg MJ, Marchetti A, Murray S, Opdam FJ, Patterson SD, Patton S, Pinto C, Rouleau E, Schuuring E, Sterck S, Taron M, Tejpar S, Timens W, Thunnissen E, van de Ven PM, Siebers AG, Dequeker E. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv. 2013;462(1):27–37. [PubMed: 23250354]
Copyright 2014 by the National Academy of Sciences. All rights reserved.
Bookshelf ID: NBK195941


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (593K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...